SCHEMBL5239008

SCHEMBL5239008

O=C1CCN(Cc2cccc3ccccc23)C(=O)[C@H](Cc2ccc(Cl)cc2)N1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CLPP Q16740 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ TNF P01375 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ CXCR3 P49682 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ HDAC1 Q13547 3/20 0.41
▸ HDAC8 Q9BY41 3/20 0.41
▸ HDAC6 Q9UBN7 3/20 0.41
▸ SSTR1 P30872 1/20 0.41
▸ SSTR2 P30874 1/20 0.41
▸ SSTR4 P31391 1/20 0.41
▸ SSTR3 P32745 1/20 0.41
▸ SSTR5 P35346 1/20 0.41
▸ OPRK1 P41145 3/20 0.40
▸ DRD4 P21917 1/20 0.39
▸ CTNNB1 P35222 2/20 0.39
▸ TCF7 P36402 2/20 0.39
▸ BCL9 O00512 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7094153 0.90 L3MBTL1 (0.43) CLPPMAPTMEN1KMT2AL3MBTL1
SCHEMBL5232940 0.89 TACR2 (0.43) CLPPMAPTMEN1KMT2ACXCR3
SCHEMBL5229554 0.89 TACR2 (0.43) CLPPMAPTMEN1KMT2ACXCR3
SCHEMBL5234092 0.80 KMT2A (0.67) MAPTTNFMEN1KMT2AL3MBTL1
SCHEMBL5230507 0.80 MAPT (0.43) MAPTMEN1KMT2AL3MBTL1HDAC1
SCHEMBL877505 0.78 DDB1 (0.57) CXCR3L3MBTL1HDAC1HDAC8HDAC6
SCHEMBL877537 0.78 DDB1 (0.57) CXCR3L3MBTL1HDAC1HDAC8HDAC6
SCHEMBL5232904 0.74 TACR2 (0.39) CXCR3HDAC1HDAC8HDAC6OPRK1
SCHEMBL7468758 0.73 OPRK1 (0.65) MAPTMEN1KMT2AL3MBTL1HDAC1
SCHEMBL874099 0.73 OPRK1 (0.65) MAPTMEN1KMT2AL3MBTL1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US claimed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US claimed
EP-1296961-B1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-02-14 — — EP disclosed
EP-1296961-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-04-02 — — EP disclosed
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US disclosed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US disclosed
WO-2001090083-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation BDKRB2, NPSR1, BDKRB1 CLPP 4145/4885MAPT 4885/4885TNF 4833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback